Inflammatory Disease News and Research

RSS

GlaxoSmithKline and Cellzome announce major strategic alliance

Cellzome Inc. and GlaxoSmithKline have announced the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.

10 Sep 2008

New technique in blood analysis may speed diagnosis of heart attacks

Someday doctors may be able to use a blood test to confirm within minutes, instead of hours, if a patient is having a heart attack, allowing more rapid treatment that could limit damage to heart muscle.

9 Sep 2008

Researchers find cause of severe metabolic disorders

A healthy body stores fat in the form of so-called triglycerides in specialized fatty tissue as an energy reserve.

9 Sep 2008

Discovery of novel candidate gene for inflammatory bowel diseases

A study of Crohn's disease and ulcerative colitis in children has identified a gene that influences whether children get these diseases early in life, and points to a potential new target for treatment.

2 Sep 2008

MorphoSys announces publication of first MOR103 data

MorphoSys AG announced today the publication of a first data package for its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF, in the journal "Molecular Immunology".

2 Sep 2008

Researchers discover key details of how rheumatoid arthritis destroys bone

Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry. The findings are already guiding attempts to design new drugs to reverse RA-related bone loss and may also address more common forms of osteoporosis with a few adjustments.

24 Aug 2008

New discovery on how rheumatoid arthritis destroys bone

20 Aug 2008

New understanding of how white blood cell eosiniphils fights infection

U.S. and Swiss scientists have made a breakthrough in understanding how a type of white blood cell called the eosinophil may help the body to fight bacterial infections in the digestive tract, according to research published online this week in Nature Medicine

13 Aug 2008

Isis Pharmaceuticals trials C-reactive protein drug

Isis Pharmaceuticals, Inc. announced today it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP). CRP levels are frequently elevated in patients with a variety of diseases including cardiovascular disease, Crohn's disease, rheumatoid arthritis and end-stage renal disease.

13 Aug 2008

New treatment in the pipeline for leukaemia and rheumatoid arthritis

Australian scientists believe they are well on the way to developing a new treatment for leukaemia and inflammatory diseases such as rheumatoid arthritis and asthma.

10 Aug 2008

Bacterial vaginosis may increase risk of HIV infection

A common vaginal infection may make women more susceptible to contracting HIV, the virus that causes AIDS, University of North Carolina at Chapel Hill School of Public Health researchers have found.

31 Jul 2008

Newly identified risk factor for cardiovascular disease may lead to new treatments

Low levels of naturally occurring antibodies may represent an increased risk of developing cardiovascular disease, particularly stroke in men. This discovery, published in the academic journal Atherosclerosis, has now led to attempts to develop an immunization against cardiovascular disease.

31 Jul 2008

Roche starts acquisition process of ARIUS - fast tracks access to screening platform for antibody therapeutics

Roche and ARIUS Research Inc. have announced that the two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million.

23 Jul 2008

Luna awarded NIH grant for fullerene-based nanomedicines as allergy treatments

Luna Innovations Incorporated has announced the award of a $1.6 million Research Project Grant (R01) from the National Institutes of Health (NIH) to investigate the use of fullerene-based nanomedicines as a pathway to treat allergies and other inflammatory diseases.

22 Jul 2008

EpiCept and GNI partner to develop anti-viral hepatitis drug in Asia

GNI Ltd and EpiCept Corporation have announced that they have reached agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-IND and clinical development in China immediately.

17 Jul 2008

Farm-raised tilapia fish contains potentially dangerous fatty acid combination

"Farm-raised tilapia, one of the most highly consumed fish in America, has very low levels of beneficial omega-3 fatty acids and, perhaps worse, very high levels of omega-6 fatty acids, according to new research from Wake Forest University School of Medicine.

8 Jul 2008

Post-traumatic stress disorder causes early death from heart disease

Vietnam veterans who experienced posttraumatic stress disorder (PTSD) were twice as likely to die from heart disease as veterans without PTSD, a new Geisinger study finds.

8 Jul 2008

Fourth edition of the British National Formulary for Children

The fourth edition of the British National Formulary for Children (BNFC) arms health professionals with the information they need to tackle recent controversial health concerns in young people, including rising rates of teenage pregnancy and the increasing incidence of sexually transmitted infections.

3 Jul 2008

GILZ protein may have big role in making more bone and less fat

A small protein may have a big role in helping you make more bone and less fat, researchers say. "The pathways are parallel, and the idea is if you can somehow disrupt the fat production pathway, you will get more bone," says Dr. Xingming Shi, bone biologist at the Medical College of Georgia Institute of Molecular Medicine and Genetics.

1 Jul 2008

Discovery of possible new way to block inflammation in autoimmune disease

Researchers from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), have identified a promising new target for autoimmune disease treatment - a cell-surface receptor called DR3.

23 Jun 2008